Sobi - Swedish Orphan Biovitrum AB (publ) | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Swedish Orphan Biovitrum AB (Sobi) is a biopharmaceutical company based in Stockholm, Sweden. It focuses on developing, manufacturing, and marketing treatments for rare diseases, particularly in hematology, immunology, and specialty care. Sobi specializes in innovative therapies for conditions such as hemophilia, inflammation, genetic and metabolic diseases, and amyotrophic lateral sclerosis (ALS).

The company offers a range of biologics and protein-based therapies, with a strong emphasis on orphan drugs for rare diseases. Sobi has developed treatments like recombinant clotting factors for hemophilia A and B, as well as enzyme replacement therapies. It also collaborates with partner companies to manufacture specialty products and has established strategic partnerships with organizations like Amgen and Biogen Idec. Sobi operates globally, serving hospitals, specialty clinics, and healthcare providers across Europe, North America, the Middle East, Russia, and Asia. With a robust clinical development pipeline and over 150 clinical trials, Sobi is committed to advancing treatments for rare diseases and has reported significant revenue growth, particularly in Europe and the United States.